ArticleActa Cardiologica Sinica2023
2023 Consensus of Taiwan Society of Cardiology on the Pharmacological Treatment of Chronic Heart Failure.
Article in Acta Cardiologica Sinica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Microbial metabolites associated in stool and left ventricle of heart failure patients revealed by meta-analysis.Scientific reports · 2025Pooled it
- Implementation of the Get With The Guidelines-Heart Failure Adherence to Science, Implementation in Asia (GWTG-HF A.S.I.A.) Program in Taiwan.Journal of the American Heart Association · 2026Article
- Incretin-based therapy: An update focusing on the major revolution in cardiovascular-kidney-metabolic health.Journal of the Chinese Medical Association : JCMA · 2025Review
- Early Initiation of Guideline-Directed Medical Therapy Improves Outcomes in Heart Failure with Reduced Ejection Fraction Patients without Significant Risk of Nephrotoxicity.Acta Cardiologica Sinica · 2025Article
- Prognostic implication of heart failure stage and left ventricular ejection fraction for patients with in-hospital cardiac arrest: a 16-year retrospective cohort study.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Clinical Impact of the Early Use of Sacubitril/Valsartan in Newly Diagnosed Heart Failure and Reduced Ejection Fraction.Acta Cardiologica Sinica · 2025Article
- Aptasensor-based point-of-care detection of cardiac troponin biomarkers for diagnosis of acute myocardial infarction.The Kaohsiung journal of medical sciences · 2025Review
- Are There Any Renoprotective Effects of SGLT2 Inhibitors in Heart Transplant Recipients with Diabetes?Acta Cardiologica Sinica · 2025Article
- 2025 Update Consensus ofActa Cardiologica Sinica · 2025Article
- It's Prime Time for Primary Prevention.Acta Cardiologica Sinica · 2024Article
- The Significant Role of Post-Acute Care Programs in Individuals with Heart Failure.Acta Cardiologica Sinica · 2024Article
- Feasibility of Short-Term Use of Ivabradine in Critical Ill Patients Who Have Atrial Fibrillation and Tachycardia.Acta Cardiologica Sinica · 2024Article
- 2024 Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction.Acta Cardiologica Sinica · 2024Article
- Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.Clinical and molecular hepatology · 2024Review
- A Guide Not Just for the Faint of Heart - Faster and Greater.Acta Cardiologica Sinica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 14 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of heart failure is increasing, causing a tremendous burden on health care systems around the world. Although mortality rate of heart failure has been significantly reduced by several effective agents in the past 3 decades, yet it remains high in observational studies. More recently, several new classes of drugs emerged with significant efficacy in reducing mortality and hospitalization in chronic heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). To integrate these effective therapies and prioritize them in the management of Asian patients, Taiwan Society of Cardiology has recently appointed a working group to formulate a consensus of pharmacological treatment in patients with chronic heart failure. Based on most updated information, this consensus provides rationales for prioritization, rapid sequencing, and in-hospital initiation of both foundational and additional therapies for patients with chronic heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.